Crohn's disease Trials in Cincinnati, United States
Conditions / Crohn's disease / Cincinnati, United States
Clinical trials for Crohn's disease investigate a range of treatment strategies and patient populations.
73 total trials for this combination
Showing top 10 of 73 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03105102 | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03345823 | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03105128 | A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease | COMPLETED | PHASE3 |
| NCT02914600 | Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease | TERMINATED | PHASE3 |
| NCT02914561 | Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease | COMPLETED | PHASE3 |
| NCT03345836 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy | COMPLETED | PHASE3 |
| NCT01369342 | A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) | COMPLETED | PHASE3 |
| NCT03104413 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment | COMPLETED | PHASE3 |
| NCT03345849 | A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies | COMPLETED | PHASE3 |
| NCT01369355 | A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) | COMPLETED | PHASE3 |